Eckert & Ziegler Strahlen- und Medizintechnik AG / DE0005659700
08.01.2024 - 10:00:03Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
| Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Alliance Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates 08.01.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, Germany and Cambridge, Mass., – 8 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Eckert & Ziegler will support ARTBIO to establish manufacturing and delivery of its pipeline therapies using its proprietary AlphaDirectTM Lead-212 (Pb-212) isolation technology. The collaboration aims to expedite the development of Lead-212 based alpha radioligand therapies, starting with the clinical development of ARTBIO’s lead asset of AB001 in prostate cancer. Initially focussing on the US market and utilizing Eckert & Ziegler’s facilities in Boston, both companies plan to evaluate a global operations expansion at a later stage. Besides the US, Eckert & Ziegler’s global CMO service network includes manufacturing sites in Berlin, Germany and Jintan, China. The radioisotope Lead-212 is an alpha precursor used as an active substance in cancer treatment. As part of a radiopharmaceutical product, the radioisotope enables precision treatment of tumor cells, while minimizing the damage to healthy adjacent tissue. With several studies ongoing, Pb-212-labeled compounds represent one of the most promising therapeutic approaches in nuclear medicine. "We are excited to collaborate with ARTBIO in this transformative venture,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler. ”By combining Eckert & Ziegler's expertise in radiopharmaceutical manufacturing with ARTBIO's innovative approach to therapeutic solutions, we are poised to make substantial progress in advancing Lead-212 based alpha therapies." "We are pleased to partner with Eckert & Ziegler to expand our distributed manufacturing network in order to reliably and efficiently deliver alpha radioligand therapies to patients," said Conrad Wueller, Director, Strategy and Operations at ARTBIO. "Eckert & Ziegler's vast experience and global footprint in radiopharmaceutical manufacturing and distribution will be critical as we advance our pipeline and aim to get our therapeutic candidates to people who need them most." About Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse. Contributing to saving lives. About ARTBIO ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb-212) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirectTM technology, a first-of-its-kind Pb-212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing three pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital. Contact Eckert & Ziegler AG Robert-Rössle-Str. 10, 13125 Berlin, Deutschland Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing karolin.riehle@ezag.de / jan.schoepflin@ezag.de Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com ARTBIO Amanda Breeding amanda.breeding@vergescientific.com +1 615-457-4734 08.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | karolin.riehle@ezag.de |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1809641 |
| End of News | EQS News Service |
| |
